This systematic review estimated MCI and AD prevalence and the population potentially eligible for amyloid-targeting therapy. It pooled population-based studies from 2020 to 2026, covering 312,204 participants aged 60 and over in mainland China. Pooled prevalence was 21.21% (95% CI 17.41–25.01%) for MCI and 4.72% (95% CI 3.13–6.31%) for AD. A stepwise funnel model then applied rates of consultation, clinical diagnosis, biomarker testing and amyloid positivity. Under current conditions, 39,825 people were potentially eligible for amyloid-targeting therapy, against 14.17 million without these constraints. Most studies were of moderate quality, heterogeneity was extreme (I² 99.7–99.8%), and age-stratified evidence was limited.
Why it is interesting: The modelled eligible population falls from 14.17 million to 39,825 once current consultation, diagnosis and biomarker testing rates are applied. The gap places the main constraint on access in diagnostic pathways, not in disease prevalence.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.